Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge

Genetic Vaccines and Therapy

Volumn 8, Issue , 2010, Pages

  Commander, Nicola J ^a   Brewer, James M ^b   Wren, Brendan W ^c   Spencer, Stephen A ^a   MacMillan, Alastair P ^a   Stack, Judith A ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; P IALB DNA VACCINE; P OMP25 DNA VACCINE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BAGG ALBINO MOUSE; BRUCELLA MELITENSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG UTILIZATION; IMMUNE RESPONSE; IMMUNOGENICITY; LIPOSOMAL DELIVERY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; VACCINATION;

BRUCELLA; BRUCELLA MELITENSIS; MURINAE;

EID: 77954558213     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-8-5     Document Type: Article

References (42)

1. Yagupsky P, Baron EJ. Laboratory exposures to brucellae and implications for bioterrorism. Emerg Infect Dis 2005, 11:1180-5.
2. Blasco JM. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med 1997, 31:275-83. 10.1016/S0167-5877(96)01110-5, 9234451.
3. Garin-Bastuji B, Blasco JM, Grayon M, Verger JM. Brucella melitensis infection in sheep: present and future. Vet Res 1998, 29:255-74.
4. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol 2002, 90:479-96. 10.1016/S0378-1135(02)00255-9, 12414166.
5. Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine 2006, 24(19):4179-87. 10.1016/j.vaccine.2006.01.038, 16481077.
6. Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godfroid J, et al. Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infect Immun 2001, 69:6264-70. 10.1128/IAI.69.10.6264-6270.2001, 98760, 11553569.
7. Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, et al. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2002, 70:2507-11. 10.1128/IAI.70.5.2507-2511.2002, 127889, 11953389.
8. Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, et al. A DNA vaccine encoding Cu, Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2003, 71:4857-61. 10.1128/IAI.71.9.4857-4861.2003, 187304, 12933826.
9. Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 2005, 73(10):6537-46. 10.1128/IAI.73.10.6537-6546.2005, 1230944, 16177328.
10. Yang X, Hudson M, Walters N, Bargatze RF, Pascual DW. Selection of protective epitopes for Brucella melitensis by DNA vaccination. Infect Immun 2005, 73(11):7297-303. 10.1128/IAI.73.11.7297-7303.2005, 1273852, 16239526.
11. Gupta VK, Rout PK, Vihan VS. Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16 M. Res Vet Sci 2007, 82(3):305-13. 10.1016/j.rvsc.2006.07.014, 17014873.
12. Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16 M genes. Vaccine 2007, 25:43-54. 10.1016/j.vaccine.2006.07.046, 17049676.
13. González-Smith A, Vemulapalli R, Andrews E, Oñate A. Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2. Immunobiology 2006, 211(1-2):65-74. 10.1016/j.imbio.2005.09.004, 16446171.
14. Rosinha GM, Myioshi A, Azevedo V, Splitter GA, Oliveira SC. Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation. J Med Microbiol 2002, 51(8):661-71.
15. Yu DH, Li M, Hu XD, Cai H. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine 2007, 17(25):37-38.
16. Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31(Omp31) and recombinant Omp31 boosting. Clin Vaccine Immunol 2007, 14(7):869-74. 10.1128/CVI.00472-06, 1951060, 17428946.
17. Muñoz-Montesino C, Andrews E, Rivers R, González-Smith A, Moraga-Cid G, Folch H, Céspedes S, Oñate AA. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect Immun 2004, 72(4):2081-7. 10.1128/IAI.72.4.2081-2087.2004, 375181, 15039330.
18. Saez D, Guzman I, Andrews E, Cabrera A, Onate A. Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu Zn superoxide dismutase (SOD) gene in cattle. Vet Microbiol 2008, 129(2-3):396-403. 10.1016/j.vetmic.2007.11.015, 18164561.
19. Tollefsen S, Vordermeier M, Olsen I, Storset AK, Reitan LJ, Clifford D, et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand J Immunol 2003, 57:229-38. 10.1046/j.1365-3083.2003.01218.x, 12641651.
20. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22:2489-93. 10.1016/j.vaccine.2003.11.073, 15193413.
21. O'Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods 2006, 40(1):10-9. 10.1016/j.ymeth.2006.05.017, 16997709.
22. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000, 97:811-6. 10.1073/pnas.97.2.811, 15413, 10639162.
23. Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, O'Hagan DT, Donnelly JJ, Ott G, McDonald DM. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol 2003, 225:12-20. 10.1016/j.cellimm.2003.09.003, 14643300.
24. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigens. J Immunol 1998, 161(8):4000-7.
25. Babiuk LA, van Drunen LD, Loehr BI, Uwiera R. Veterinary applications of DNA vaccines. Dev Biol (Basel) 2000, 104:73-81.
26. Ishii N, Fukushima J, Kaneko T, Okada E, Tani K, Tanaka SI, Hamajima K, Xin KQ, Kawamoto S, Koff W, Nishioka K, Yasuda T, Okuda K. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997, 13(16):1421-8. 10.1089/aid.1997.13.1421, 9359662.
27. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176(12):7335-45.
28. Perrie Y, McNeil S, Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J Drug Target 2003, 11(8-10):555-63. 10.1080/10611860410001670071, 15203925.
29. Hiszczyńska-Sawicka E, Li H, Xu JB, Ole{ogonek}dzka G, Kur J, Bickerstaffe R, Stankiewicz M. Comparison of immune response in sheep immunized with DNA vaccine encoding Toxoplasma gondii GRA7 antigen in different adjuvant formulations. Exp Parasitol 2010, 124(4):365-72. 10.1016/j.exppara.2009.11.015, 19962376.
30. Murphy EA, Sathiyaseelan J, Parent MA, Zou B, Baldwin CL. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 2001, 103(4):511-8. 10.1046/j.1365-2567.2001.01258.x, 1783270, 11529943.
31. Weynants V, Walravens K, Didembourg C, Flanagan P, Godfroid J, Letesson JJ. Quantitative assessment by flow cytometry of T-lymphocytes producing antigen-specific gamma-interferon in Brucella immune cattle. Vet Immunol Imunopathol 1998, 66(3-4):309-20.
32. Araya LN, Winter AJ. Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum. Infect Immun 1990, 58(1):254-6. 258438, 2104599.
33. Pavlov H, Hogarth M, McKenzie IF, Cheers C. In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection. Cell Immunol 1982, 71(1):127-38. 10.1016/0008-8749(82)90502-0, 6814766.
34. Mielke ME. T cell subsets in granulomatous inflammation and immunity to L. Monocytogenes and B. abortus. Behring Inst Mitt 1991, 88:99-111.
35. Zhan Y, Kelso A, Cheers C. Differential activation of Brucella-reactive CD4+ T cells by Brucella infection or immunization with antigenic extracts. Infect Immun 1995, 63(3):969-75. 173097, 7868269.
36. Zhan Y, Cheers C. Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun 1993, 61(11):4899-901. 281252, 8406893.
37. Bernstein DI, Cardin RD, Bravo FJ, Strasser JE, Farley N, Chalk C, Lay M, Fairman J. Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin Vaccine Immunol 2009, 16(5):699-705. 10.1128/CVI.00370-08, 2681593, 19279167.
38. Rosada RS, de la Torre LG, Frantz FG, Trombone AP, Zárate-Bladés CR, Fonseca DM, Souza PR, Brandão IT, Masson AP, Soares EG, Ramos SG, Faccioli LH, Silva CL, Santana MH, Coelho-Castelo AA. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol 2008, 22:9-38.
39. Eschenbrenner M, Wagner MA, Horn TA, Kraycer JA, Mujer CV, Hagius S, Elzer P, DelVecchio VG. Comparative proteome analysis of Brucella melitensis vaccine strain Rev 1 and a virulent strain, 16 M. J Bacteriol 2002, 184(18):4962-70. 10.1128/JB.184.18.4962-4970.2002, 135307, 12193611.
40. Coleman SA, Minnick MF. Establishing a direct role for the Bartonella bacilliformis invasion-associated locus B (IalB) protein in human erythrocyte parasitism. Infect Immun 2001, 69(7):4373-81. 10.1128/IAI.69.7.4373-4381.2001, 98509, 11401976.
41. Garmory HS, Brown KA, Titball RW. DNA vaccines: improving expression of antigens. Genet Vaccines Ther 2003, 1(1):2. 10.1186/1479-0556-1-2, 244903, 14606963.
42. Singha H, Mallick AI, Jana C, Isore DP, Goswami TK, Srivastava SK, Azevedo VA, Chaudhuri P, Owais M. Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus. Microbes Infect 2008, (10-11):1089-96. 10.1016/j.micinf.2008.05.007, 18602490.